2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma
Harold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.Peer-Reviewed Original ResearchConceptsPatient-derived xenograftsUterine leiomyosarcomaVivo activityVehicle control treatmentMedian overall survivalTumor volume differencesOral scheduleWestern blot analysisOverall survivalOral gavageAggressive malignancyPDX modelsClinical trialsSCID miceTumor measurementsULMS patientsSignificant growth inhibitionNovel ATR inhibitorTumor samplesSignificant toxicityWestern blotKinase inhibitorsATRX mutationsGene mutationsControl vehicle
2006
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis
Patton KT, Cheng L, Papavero V, Blum MG, Yeldandi AV, Adley BP, Luan C, Diaz LK, Hui P, Yang XJ. Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Modern Pathology 2006, 19: 130-140. PMID: 16357844, DOI: 10.1038/modpathol.3800504.Peer-Reviewed Original ResearchConceptsBenign metastasizing leiomyomaUterine leiomyomaUterine tumorsPolymorphic CAG repeat sequenceLow-grade uterine leiomyosarcomaBenign uterine leiomyomaSmooth muscle tumorsHuman androgen receptor geneAndrogen receptor genePulmonary leiomyomaUterine counterpartsMultiple lungPulmonary tumorsClinicopathologic analysisImmunohistochemical featuresMuscle tumorsBenign histologyUterine leiomyosarcomaRare conditionUterine leiomyomataImmunohistochemical profileInformative patientsLeiomyomaCAG repeat sequencePatients